PAG-led consortium to acquire Chennai-based API manufacturer Anjan Drug

By: |
October 12, 2020 6:18 PM

"The acquisition is part of the PAG-led consortium's strategy to create a best-in-class platform for the development and production of bulk drug ingredients," PAG said in a release.

Terms of the deal were not disclosed.

Private equity firm PAG-led consortium has reached an agreement to acquire a controlling stake in city-based active pharmaceutical ingredients (API) maker Anjan Drug Pvt. Ltd, the company announced on Monday. Terms of the deal were not disclosed.

“The acquisition is part of the PAG-led consortium’s strategy to create a best-in-class platform for the development and production of bulk drug ingredients,” PAG said in a release.

The consortium includes CX Partners and Samara Capital. Founded by C Kalaichelvan, Anjan is a leading supplier of active drug ingredients in the central nervous system therapy segment to some of the world’s largest pharmaceutical companies in markets, including the US and Europe, the release said.

According to Managing Director and head of India private equity at PAG, Nikhil Srivastava, partnering with Anjan is a key first step in the company’s plan to create the pre-eminent platform for Indian API. PAG, an Asia-focused firm, is currently investing out of its USD 6 bn PAG Asia III buyout fund and has declared plans to invest up to USD 1 bn in India over the next few years, the release added.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1BoM Q2 profit up 13% on higher interest income, lower provisioning
2On track to become Ebitda and cash positive by March 2021: Saurabh Kumar, founder, Grofers
3HDFC Life Q2 profit rises 5.6% to Rs 326 crore